Gallus BioPharmaceuticals LLC, a St. Louis company with facilities in Princeton, was acquired by DPx Holdings B.V., the companies announced Thursday.
Gallus is a manufacturer of biologic drugs, while DPx is the parent of Patheon, a pharmaceutical services business. The two Gallus sites will become the first Patheon biologic drug substance sites in the U.S., according to a news release, complementing the DPx unit’s existing sites in the Netherlands and Australia.
"We are pleased to expand our biologics business with the acquisition of Gallus BioPharmaceuticals," Jim Mullen, CEO of DPx Holdings, said in the release. "This transaction is in line with our strategy. We can now further support the needs of our customers with biologics projects by providing flexibility, leading technology solutions, commercial operations and an expanded footprint with two U.S. sites."
The deal is expected to close in the fourth quarter. Terms were not disclosed.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy